Restless Legs Syndrome 

  • Author: Ali M Bozorg, MD; Chief Editor: Selim R Benbadis, MD   more...
 
Updated: Feb 1, 2012
 

Background

Restless legs syndrome (RLS) is a neurologic movement disorder of the limbs that is often associated with a sleep complaint.[1] Patients with RLS have a characteristic difficulty in trying to depict their symptoms. They may report sensations, such as an almost irresistible urge to move the legs, that are not painful but are distinctly bothersome. RLS can lead to significant physical and emotional disability. (See Prognosis and Presentation.)

The sensations of RLS usually are worse during inactivity and often interfere with sleep, leading to walking discomfort, chronic sleep deprivation, and stress.[2] Once correctly diagnosed, RLS can usually be treated effectively and, in some secondary cases, it can even be cured. (See Treatment and Medication.)

The term RLS was used initially in the mid-1940s by Swedish neurologist Karl A. Ekbom. However, descriptions of the disorder date back to the 17th century.

RLS is often unrecognized or misdiagnosed.[3, 4] Many patients are not diagnosed until 10-20 years after symptom onset. RLS may begin at any age, even as early as infancy, but most patients who are affected severely are middle-aged or older. (See Epidemiology, Presentation, and Workup.)

Patient education

The education of patients and their families should focus on providing a better understanding of the disease and on the importance of compliance in improving the symptoms. (See Treatment and Medication.)

For patient education information, see the Sleep Disorders Center, as well as Restless Legs Syndrome (RLS), Sleep Disorders in Women, and Sleep Disorders and Aging.

Next

Etiology

The pathogenesis of RLS is unclear.[5, 6, 7, 8] Currently, the most widely accepted mechanism involves a genetic component, along with abnormalities in the central, subcortical dopamine pathways and impaired iron homeostasis.[9, 10] When centrally acting dopamine receptor antagonists are administered to patients with the syndrome, symptoms are reactivated. Results of single-photon emission computed tomography (SPECT) scanning have suggested deficiency of dopamine D2 receptors. Iron homeostasis abnormalities have been implicated through cerebrospinal fluid (CSF) iron profile measures.

In addition, investigators have shown an increased severity of RLS with decreasing availability of serotonin transporter in the brainstem, supporting the hypothesis that increasing serotonin transmission in the brain may exacerbate RLS.[11]

The genetic component of RLS tends to run to in families.[12] Various chromosomes have been implicated so far, including 12q, 14q, 9p, 20p, 4q, and 17p, in autosomal dominant and recessive fashion.[9]

Primary RLS

RLS can be primary or secondary. In most cases, RLS is a primary, idiopathic central nervous system (CNS) disorder. Such idiopathic disease can be familial in 25-75% of cases. In the familial cases, RLS appears to follow a pattern of autosomal dominant or recessive inheritance.

Patients with familial RLS tend to have an earlier age of onset (< 45 y) and slower disease progression. In some families, a progressive decrease in age of onset with successive generations (ie, genetic anticipation) has been described. Psychiatric factors, stress, and fatigue can exacerbate symptoms of RLS.

Secondary RLS [1]

RLS can develop as a result of certain conditions or factors, particularly iron deficiency and peripheral neuropathy.[3] These 2 conditions should be excluded before RLS is labeled as primary.[3] Because of the prevalence of these conditions in the general population, their association with RLS needs to be interpreted with caution.

Other causes of RLS include the following:

  • Folate or magnesium deficiency
  • Amyloidosis
  • Lumbosacral radiculopathy
  • Lyme disease
  • Monoclonal gammopathy of undetermined significance
  • Rheumatoid arthritis
  • Uremia
  • Vitamin B-12 deficiency
  • Frequent blood donation

Pregnancy is another causative factor in RLS, with the disorder thought to affect 25-40% of pregnant women. The syndrome usually subsides within a few weeks after delivery. However, in one long-term, follow-up study, women who developed RLS during pregnancy had a 4-fold increased risk of developing chronic RLS compared with women who did not have RLS when pregnant.[13]

RLS also occurs in as many as 25-50% of patients who have end-stage renal disease; these patients find their symptoms to be particularly bothersome during hemodialysis. One study found that hyperphosphatemia, anxiety, and a great degree of emotion-oriented coping with stress were independently related to the presence of RLS in patients with uremia who were taking hemodialysis therapy.[6] RLS may improve after kidney transplantation.

The following medications have been known to cause or exacerbate the symptoms of RLS:

  • Antidopaminergic medications (such as neuroleptics)
  • Diphenhydramine
  • Tricyclic antidepressants (TCAs)
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Alcohol
  • Caffeine
  • Lithium
  • Beta blockers
Previous
Next

Epidemiology

RLS affects about 5-15% of the general population of the United States. Although the exact international prevalence of the disease is uncertain, limited studies have indicated that 2-15% of the world’s population may experience symptoms of RLS.[1]

Race-, sex-, and age-related demographics

RLS affects African Americans less commonly than Caucasians; this applies even to secondary RLS caused by hemodialysis.[14]

Women are affected more commonly than men at a ratio of almost 2:1. The increased risk of RLS in women is thought to be related to parity; nulliparous women have the same risk of developing RLS when compared with age-matched men.[15] Although the prevalence of RLS increases with age, it has a variable age of onset and can occur in children. In patients with severe RLS, 33-40% had their first symptom before the age of 20 years, although the precise diagnosis of RLS was made much later. RLS usually progresses slowly to daily symptoms and severe disruption of sleep after age 50 years. Individuals with familial RLS tend to have onset of symptoms before age 45 years.

Previous
Next

Prognosis

The symptoms of RLS progress over time in about two thirds of patients. The severity of symptoms in patients with RLS ranges from mild to intolerable. Although patients experience the sensations in their legs, they also may occur in the arms or elsewhere. RLS symptoms are generally worse in the evening and night and less severe in the morning.

While RLS may present early in adult life with mild symptoms, usually by age 50 it progresses to severe, daily disruption of sleep leading to decreased daytime alertness. RLS has been associated with reduced quality of life in cross-sectional analysis.[15, 16]

Morbidity

Patients with RLS and periodic leg movements of sleep (PLMS) may be at an increased risk of developing hypertension. PLMS is associated with an autonomic surge and an increase in blood pressure.[17]

Patients may also be prone to more headaches, which are migraine and tension-type in nature. The headaches are probably secondary to disturbances in sleep associated with RLS and PLMS.

Learning and memory difficulties have also been associated with RLS, presumably secondary to disrupted nocturnal sleep.[17]

Previous
 
 
Contributor Information and Disclosures
Author

Ali M Bozorg, MD  Assistant Professor, Comprehensive Epilepsy Program, Department of Neurology, University of South Florida College of Medicine

Ali M Bozorg, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, and American Epilepsy Society

Disclosure: Pfizer Honoraria Speaking and teaching; UCB, Inc. Honoraria Speaking and teaching

Chief Editor

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Additional Contributors

Jose E Cavazos, MD, PhD, FAAN Associate Professor with Tenure, Departments of Neurology, Pharmacology, and Physiology, Program Director of the Clinical Neurophysiology Fellowship, University of Texas School of Medicine at San Antonio; Co-Director, South Texas Comprehensive Epilepsy Center, University Hospital System; Director of the San Antonio Veterans Affairs Epilepsy Center of Excellence and Neurodiagnostic Centers, Audie L Murphy Veterans Affairs Medical Center

Jose E Cavazos, MD, PhD, FAAN is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, and American Neurological Association

Disclosure: GXC Global, Inc. Intellectual property rights Medical Director - company is to develop a seizure detecting device. No conflict with any of the eMedicine articles that I wrote or edited.

William G Irr, MD Consulting Staff, Department of Neurology Service, St Luke's Episcopal Hospital of Houston

William G Irr, MD is a member of the following medical societies: American Academy of Neurology.

Disclosure: Nothing to disclose.

Juan Latorre, MD Research Fellow, Department of Physical Medicine and Spinal Cord Injury Medicine, The Institute for Rehabilitation and Research

Juan Latorre, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Erasmo A Passaro, MD, FAAN Director, Comprehensive Epilepsy Program/Clinical Neurophysiology Lab, Bayfront Medical Center, Florida Center for Neurology

Erasmo A Passaro, MD, FAAN is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association, and American Society of Neuroimaging

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; UCB Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Forest Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Restless legs syndrome. detection and management in primary care. National Heart, Lung, and Blood Institute Working Group on Restless Legs Syndrome. Am Fam Phys. Jul 1 2000;62(1):108-14. [Medline].

  2. Silber MH. Restless legs syndrome. Mayo Clin Proc. Mar 1997;72(3):261-4. [Medline].

  3. Evidente VG, Adler CH. How to help patients with restless legs syndrome. Discerning the indescribable and relaxing the restless. Postgrad Med. Mar 1999;105(3):59-61, 65-6, 73-4. [Medline].

  4. Gamaldo CE, Earley CJ. Restless legs syndrome: a clinical update. Chest. Nov 2006;130(5):1596-604. [Medline].

  5. Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc. Jul 1990;65(7):999-1006. [Medline].

  6. Takaki J, Nishi T, Nangaku M, et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis. Apr 2003;41(4):833-9. [Medline].

  7. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. Mar 2003;4(2):121-32. [Medline].

  8. Weinstock LB, Walters AS, Paueksakon P. Restless legs syndrome - Theoretical roles of inflammatory and immune mechanisms. Sleep Med Rev. Jan 16 2012;[Medline].

  9. Winkelman JW. Considering the causes of RLS. Eur J Neurol. Oct 2006;13 Suppl 3:8-14. [Medline].

  10. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. Mar 2001;18(2):128-47. [Medline].

  11. Jhoo JH, Yoon IY, Kim YK, Chung S, Kim JM, Lee SB. Availability of brain serotonin transporters in patients with restless legs syndrome. Neurology. Feb 9 2010;74(6):513-8. [Medline].

  12. Trenkwalder C, Hogl B, Winkelmann J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol. Apr 2009;256(4):539-53. [Medline].

  13. Cesnik E, Casetta I, Turri M, Govoni V, Granieri E, Strambi LF, et al. Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. Neurology. Dec 7 2010;75(23):2117-20. [Medline].

  14. Kutner NG, Zhang R, Huang Y, Bliwise DL. Racial differences in restless legs symptoms and serum ferritin in an incident dialysis patient cohort. Int Urol Nephrol. Jan 5 2012;[Medline].

  15. Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. Jan 26 2004;164(2):196-202. [Medline].

  16. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. Jun 2004;26(6):925-35. [Medline].

  17. Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med. Nov 2009;266(5):419-31. [Medline].

  18. Ondo W. Ropinirole for restless legs syndrome. Mov Disord. Jan 1999;14(1):138-40. [Medline].

  19. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. Sep 1995;10(5):634-42. [Medline].

  20. Simakajornboon N, Kheirandish-Gozal L, Gozal D. Diagnosis and management of restless legs syndrome in children. Sleep Med Rev. Apr 2009;13(2):149-56. [Medline].

  21. Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol. Dec 2004;56(6):803-7. [Medline].

  22. Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy?. Neurology. Mar 17 2009;72(11):955-60. [Medline].

  23. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12(2):192-214. [Medline].

  24. Hening WA. Restless Legs Syndrome. Curr Treat Options Neurol. Sep 1999;1(4):309-319. [Medline].

  25. Ferreri F, Rossini PM. Neurophysiological investigations in restless legs syndrome and other disorders of movement during sleep. Sleep Med. Jul 2004;5(4):397-9. [Medline].

  26. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord. Jul 30 2009;24(10):1445-52. [Medline].

  27. Shinno H, Yamanaka M, Ishikawa I, Danjo S, Nakamura Y, Inami Y. Successful treatment of restless legs syndrome with the herbal prescription Yokukansan. Prog Neuropsychopharmacol Biol Psychiatry. Feb 1 2010;34(1):252-3. [Medline].

  28. Oscroft NS, Smith IE. Oral glucocorticosteroids: effective in a case of restless legs syndrome resistant to other therapies. Sleep Med. Jun 2010;11(6):596. [Medline].

  29. Baldwin CM, Keating GM. Rotigotine transdermal patch: in restless legs syndrome. CNS Drugs. 2008;22(10):797-806. [Medline].

  30. Montplaisir J, Nicolas A, Denesle R. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. Mar 23 1999;52(5):938-43. [Medline].

  31. [Best Evidence] Bogan RK, Bornemann MA, Kushida CA, Trân PV, Barrett RW. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. Jun 2010;85(6):512-21. [Medline]. [Full Text].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.